about
Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative studyUse of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol.The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Management of cancer-associated thrombosis in people with advanced disease.FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancerDiagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? A qualitative study.The ethical decisions UK doctors make regarding advanced cancer patients at the end of life--the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study.Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative studyPatients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study.Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol.Epidemiology and pathophysiology of cancer-associated thrombosis."I didn't really understand it, I just thought it'd help": exploring the motivations, understandings and experiences of patients with advanced lung cancer participating in a non-placebo clinical IMP trial.Development and Psychometric Assessment of a Spirituality Questionnaire for Indian Palliative Care Patients.Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodologyForeign travel for advanced cancer patients: a guide for healthcare professionalsThe evidence base of palliative medicine: is inpatient palliative medicine evidence-based?The challenges of managing cancer related venous thromboembolism in the palliative care settingFurther results of the FRAGMATIC trial of thromboprophylaxis in lung cancer.Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis.Spiritual concerns in hindu cancer patients undergoing palliative care: a qualitative studyThe assessment and impact of sarcopenia in lung cancer: a systematic literature reviewImpact of a dedicated cancer-associated thrombosis service on clinical outcomes: a mixed-methods evaluation of a clinical improvement exercise.Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative studyA feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study prMalignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins.Low-molecular-weight heparin and survival in lung cancer.International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer.Treatment of painful hypertrophic osteoarthropathy associated with non-small cell lung cancer with octreotide: a case report and review of the literature.Heparins and cancer survival: where do we stand?The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?Challenges faced by palliative care physicians when caring for doctors with advanced cancer.A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICThromboembolic disease and breathlessness.Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis."Post-thrombotic panic syndrome": A thematic analysis of the experience of venous thromboembolism.Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients: a qualitative study.Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.Shark cartilage in the water: one size does not fit all.Primary thromboprophylaxis in hospices: the association between risk of venous thromboembolism and development of symptoms.
P50
Q30576135-FE6488D2-A980-4044-B79B-8B4DB403C0BDQ31088061-FC7EF09A-D59D-4ED4-83F3-9C126E207757Q33376620-D0297D7E-3954-43DD-ACF9-7715E83C2B04Q33404714-B1F0414D-117E-4072-B1B2-6EA94DA12BF0Q33414115-5A573048-E63F-496E-847B-049FA81C4359Q33508936-C77D9633-BE52-4A3F-8438-925815842514Q34346557-1A738909-C5B9-4009-9652-28AA0FE7527DQ34402787-BA9442AA-D6AD-4CFC-B5F0-554FFD647141Q34441423-FDA3B984-8799-44FA-8983-D307151C3FFBQ35142746-091602C7-6EF9-49C4-BB25-F01894B013CDQ35708619-83EE7C35-E820-4C69-91D3-C73082A7BB01Q35860789-B07B114B-D4E5-4E71-861F-BA5157F380F2Q36083195-2AC23326-7A99-48CF-8124-CA3C60812FAAQ36622270-D4228775-3D84-47A3-BEC4-5315DAE26C73Q36779739-65521ECD-3BBB-4CC3-8176-0C6383EF7E17Q36875653-2F06E1A0-FC24-4E46-B9FE-466971D869A0Q36974038-5A191C10-704F-4C87-A800-5670A8965E53Q36995852-A29D8DC1-4D89-4D6B-BB55-68510D6DABE5Q37060713-96E6A5A0-DE25-41E7-9249-D9CE932AFB97Q37176707-3B00FD0B-2497-4334-9B28-D6087CDD2818Q37176805-94F1724E-8F4C-4A61-BA59-A1299211B297Q37516578-F5DFAFB1-A6DC-4BFB-ACE5-717A9EDB701DQ37516663-D5CDE56E-911F-48AB-8161-241C7963AAD5Q37702182-53B46B90-73FD-4E68-85B1-D4672E188B6FQ37729777-A0C67265-F790-40D2-95A0-3E69E8FCDA08Q37799290-4D37D169-B386-4AAD-9EE0-3B1B9950209FQ38017363-835F4FED-6CFB-491B-B542-E6BA4E06D50DQ38065344-A88FC896-3CC3-4864-8A5A-6E8870AA43C9Q38198004-7AA7C703-0E7F-453E-B33E-1B3C313716C2Q38214957-D3B907EC-2124-4A16-B06B-5B052DAE2D72Q38560196-654BDF34-1F18-4207-B9E2-013FD5B72BE8Q38572832-ACDEA704-16CE-4FB0-BFD8-62E6A1F2A17AQ38613522-C925379A-6B40-4EC6-BB68-F2CB637B7EACQ38878594-2C8D6D45-0E66-42CC-A56B-0B695A1EABA6Q38938521-317C25A6-BE25-4BD3-89A8-905FF28B7912Q39407445-6A57AB5D-08BF-418F-A728-D4765992022CQ40070964-CDCF875B-B037-46BD-B7A3-B0837DA74EAEQ40175697-89730D87-4119-41B5-BAA9-CF4ED49480C8Q43131479-AA524EB0-2BE6-4337-90B6-07C3A5D58B7BQ43488325-87814DBF-C2B7-4FB5-B9C4-1778F8DB531A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Simon Noble
@ast
Simon Noble
@en
Simon Noble
@es
Simon Noble
@nl
Simon Noble
@sl
type
label
Simon Noble
@ast
Simon Noble
@en
Simon Noble
@es
Simon Noble
@nl
Simon Noble
@sl
prefLabel
Simon Noble
@ast
Simon Noble
@en
Simon Noble
@es
Simon Noble
@nl
Simon Noble
@sl
P106
P1153
8678954600
P21
P31
P496
0000-0001-5425-2383